Singular Genomics Systems, Inc.
OMICDelisted Feb 21, 2025- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001850906
Singular Genomics Systems, Inc. was delisted on Feb 21, 2025; its insiders filed their last Form 4 on Feb 27, 2025; 20 institutions reported holding it in 13F filings for Q4 2024, worth $21.5M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Singular Genomics Systems, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Singular Genomics Systems, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Tang Kevin C | 10% Owner | 0Indirect | Feb 27, 2025 | 0 |
| Tang Capital Partners LP | 10% Owner | 0Indirect | Feb 27, 2025 | 0 |
| Tang Capital Management LLC | 10% Owner | 0Indirect | Feb 27, 2025 | 0 |
| Barker David L | Director | 0Indirect | Feb 25, 2025 | 0 |
| Pellini Michael J | Director | 0Indirect | Feb 25, 2025 | 0 |
| Mardis Elaine R | Director | – | Feb 25, 2025 | 0 |
| Kamdar Kim P. | Director | 0Indirect | Feb 25, 2025 | 0 |
| Ryan Jason | Director | – | Feb 25, 2025 | 0 |
| Meeter Dalen | Chief Financial Officer | 0 | Feb 25, 2025 | 0 |
| Glezer Eli N. | Chief Scientific Officer | 0 | Feb 25, 2025 | 0 |
| Spaventa Andrew | Chief Executive Officer | 0Indirect | Feb 25, 2025 | 0 |
| Eisenberg Marcia | Director | – | Feb 25, 2025 | 0 |
| Ghai Jyotsna | Chief Operating Officer | 0 | Feb 25, 2025 | 0 |
| Ropp Sam | Chief Commercial Officer | 16,750 | Mar 19, 2024 | 0 |
| Daly David | President and Chief Operating | – | Mar 8, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 14, 2025 (view filing) | Feb 14 | Same day | Spaventa AndrewChief Executive Officer | SSale | −800 | $19.89 | −$15.9K | −35.8%1.43K after | |
| Dec 17, 2024 (view filing) | Dec 16 | 1 day | Spaventa AndrewChief Executive Officer | SSale | −180 | $20.16 | −$3.63K | −22.2%631 after | |
| Nov 13, 2024 (view filing) | Nov 12 | 1 day | Spaventa AndrewChief Executive Officer | SSale | −695 | $22.55 | −$15.7K | −31.1%1.54K after | |
| Sep 18, 2024 (view filing)4:31 PM ET | Sep 16-18 | 2 days | Tang Kevin C and 2 others10% Owner | PPurchase | +122.4K | $14.75 | +$1.81M | +49.0%372.0K after | 3 lots |
| Sep 17, 2024 (view filing) | Sep 15 | 2 days | Spaventa AndrewChief Executive Officer | SSale | −175 | $12.38 | −$2.17K | −21.6%637 after | |
| Nov 20, 2023 (view filing)4:31 PM ET | Nov 16-17 | 4 days | Spaventa AndrewChief Executive Officer | PPurchase | +118.5K | $0.4188 | +$49.6K | +3.0%4.06M after | 2 lots |
| Nov 20, 2023 (view filing)4:30 PM ET | Nov 16 | 4 days | Glezer Eli N.Chief Scientific Officer | PPurchase | +200.0K | $0.4282 | +$85.6K | +4.6%4.57M after | |
| Aug 15, 2023 (view filing) | Aug 11-15 | 4 days | Kamdar Kim P.Director | SSale | −631.6K | $0.5741 | −$362.6K | −14.4%3.76M after | 3 lots |
| May 18, 2023 (view filing) | May 17 | 1 day | Glezer Eli N.Chief Scientific Officer | PPurchase | +170.0K | $0.82 | +$139.4K | +4.1%4.36M after | |
| Dec 13, 2022 (view filing) | Dec 12 | 1 day | Glezer Eli N.Chief Scientific Officer | PPurchase | +50.0K | $2.00 | +$100.0K | +1.2%4.18M after | |
| May 19, 2022 (view filing) | May 18 | 1 day | Pellini Michael JDirector | PPurchase | +26.8K | $3.30 | +$88.6K | +37.0%99.3K after |